Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Kahán Z[au]:

Levél az emlőrák felismerésétől az emlőrákos betegek rehabilitációjáig tartó folyamat javításának érdekében. A III. Emlőrák Konszenzuskonferencia munkacsoportjainak és szervezőbizottságának vezetői:. et al. Magy Seb. (2016)

A myriad of roles of miR-25 in health and disease. Sárközy M et al. Oncotarget. (2018)

[Breast cancer: patient care, rehabilitation, psychooncology]. Kahán Z et al. Magy Onkol. (2016)

Search results

Items: 1 to 50 of 101

1.

Selective Heart Irradiation Induces Cardiac Overexpression of the Pro-hypertrophic miR-212.

Sárközy M, Gáspár R, Zvara Á, Kiscsatári L, Varga Z, Kővári B, Kovács MG, Szűcs G, Fábián G, Diószegi P, Cserni G, Puskás LG, Thum T, Kahán Z, Csont T, Bátkai S.

Front Oncol. 2019 Jul 16;9:598. doi: 10.3389/fonc.2019.00598. eCollection 2019.

2.

Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy.

Biro E, Kahan Z, Kalman J, Rusz O, Pakaski M, Irinyi T, Kelemen G, Dudás R, Drotos G, Hamvai C.

In Vivo. 2019 Jul-Aug;33(4):1381-1392. doi: 10.21873/invivo.11615.

3.

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer.

Tőkés AM, Rusz O, Cserni G, Tóth E, Rubovszky G, Tőkés T, Vízkeleti L, Reiniger L, Kószó R, Kahán Z, Kulka J, Donia M, Vörös A, Szallasi Z.

Acta Oncol. 2019 Jul 4:1-9. doi: 10.1080/0284186X.2019.1633015. [Epub ahead of print]

PMID:
31271119
4.

RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia.

Sántha D, Illés A, Aradi I, Horvát-Karajz K, Kahán Z.

Future Oncol. 2019 Jun;15(18):2083-2092. doi: 10.2217/fon-2018-0891. Epub 2019 Jun 18.

PMID:
31210542
5.
6.

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.

Rusz O, Kószó R, Dobi Á, Csenki M, Valicsek E, Nikolényi A, Uhercsák G, Cserháti A, Kahán Z.

Onco Targets Ther. 2018 Sep 4;11:5459-5463. doi: 10.2147/OTT.S170736. eCollection 2018.

7.

Prone Positioning on a Belly Board Decreases Rectal and Bowel Doses in Pelvic Intensity-Modulated Radiation Therapy (IMRT) for Prostate Cancer.

Kószó R, Varga L, Fodor E, Kahán Z, Cserháti A, Hideghéty K, Együd Z, Szabó C, Borzási E, Szabó D, Müllner K, Varga Z, Maráz A.

Pathol Oncol Res. 2019 Jul;25(3):995-1002. doi: 10.1007/s12253-018-0436-2. Epub 2018 Jun 7.

PMID:
29882196
8.

Daily Setup Accuracy, Side-effects and Quality of Life During and After Prone Positioned Prostate Radiotherapy.

Varga L, Kószó RL, Fodor E, Cserháti A, Varga Z, Darázs B, Kahán Z, Hideghéty K, Borzási E, Szabó D, Müllner K, Maráz A.

Anticancer Res. 2018 Jun;38(6):3699-3705. doi: 10.21873/anticanres.12648.

PMID:
29848730
9.

LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.

Rusz O, Papp O, Vízkeleti L, Molnár BÁ, Bende KC, Lotz G, Ács B, Kahán Z, Székely T, Báthori Á, Szundi C, Kulka J, Szállási Z, Tőkés AM.

Cancer Chemother Pharmacol. 2018 Jul;82(1):139-147. doi: 10.1007/s00280-018-3602-z. Epub 2018 May 16.

PMID:
29770955
10.

A myriad of roles of miR-25 in health and disease.

Sárközy M, Kahán Z, Csont T.

Oncotarget. 2018 Apr 20;9(30):21580-21612. doi: 10.18632/oncotarget.24662. eCollection 2018 Apr 20. Review.

11.

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.

Maráz A, Cserháti A, Uhercsák G, Szilágyi É, Varga Z, Révész J, Kószó R, Varga L, Kahán Z.

BMC Cancer. 2018 Mar 15;18(1):296. doi: 10.1186/s12885-018-4209-9.

12.

A simple clinical method for predicting the benefit of prone vs. supine positioning in reducing heart exposure during left breast radiotherapy.

Kahán Z, Rárosi F, Gaál S, Cserháti A, Boda K, Darázs B, Kószó R, Lakosi F, Gulybán Á, Coucke PA, Varga Z.

Radiother Oncol. 2018 Mar;126(3):487-492. doi: 10.1016/j.radonc.2017.12.021. Epub 2018 Jan 17.

13.

Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results.

Maráz A, Csejtei A, Kocsis J, Szűcs M, Kahán Z, Bodoky G, Dank M, Mangel L, Révész J, Varga Z, Géczi L.

Pathol Oncol Res. 2019 Jan;25(1):149-156. doi: 10.1007/s12253-017-0317-0. Epub 2017 Oct 13.

PMID:
29027615
14.

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.

Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, André F.

Breast Cancer Res. 2017 Feb 10;19(1):18. doi: 10.1186/s13058-017-0807-8.

15.

Levél az emlőrák felismerésétől az emlőrákos betegek rehabilitációjáig tartó folyamat javításának érdekében.

A III. Emlőrák Konszenzuskonferencia munkacsoportjainak és szervezőbizottságának vezetői:, Forrai G, Lázár G, Cserni G, Polgár C, Horváth Z, Kahán Z, Kásler M, Svébis M.

Magy Seb. 2016 Dec;69(4):203-207. Hungarian. No abstract available.

PMID:
27991026
16.

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G.

Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8.

PMID:
27502725
17.

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.

Kószó R, Sántha D, Büdi L, Erfán J, Győrfy K, Horváth Z, Kocsis J, Landherr L, Hitre E, Máhr K, Pajkos G, Pápai Z, Kahán Z.

Pathol Oncol Res. 2017 Jul;23(3):505-511. doi: 10.1007/s12253-016-0129-7. Epub 2016 Oct 22.

PMID:
27771885
18.

[Breast cancer: patient care, rehabilitation, psychooncology].

Kahán Z, Szántó I, Molnár M, Rohánszky M, Koncz Z, Mailáth M, Kapitány Z, Dudás R.

Magy Onkol. 2016 Sep;60(3):258-68. Epub 2016 Jun 10. Review. Hungarian.

19.

[Systemic therapy of breast cancer: practice guideline].

Horváth Z, Boér K, Dank M, Kahán Z, Kocsis J, Kövér E, Pajkos G, Pikó B, Rubovszky G, Eckhardt S.

Magy Onkol. 2016 Sep;60(3):241-57. Epub 2016 Jul 14. Review. Hungarian.

20.

[3rd Hungarian Breast Cancer Consensus Conference - Radiotherapy Guidelines].

Polgár C, Kahán Z, Csejtei A, Gábor G, Landherr L, Mangel L, Mayer Á, Fodor J.

Magy Onkol. 2016 Sep;60(3):229-39. Epub 2016 Jun 15. Hungarian.

21.

High-dose Radiation Induced Heart Damage in a Rat Model.

Kiscsatári L, Sárközy M, Kővári B, Varga Z, Gömöri K, Morvay N, Leprán I, Hegyesi H, Fábián G, Cserni B, Cserni G, Csont T, Kahán Z.

In Vivo. 2016 09-10;30(5):623-31.

PMID:
27566082
22.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators.

Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5.

PMID:
27501767
23.

Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone.

Kiscsatári L, Varga Z, Schally AV, Gáspár R, Nagy CT, Giricz Z, Ferdinandy P, Fábián G, Kahán Z, Görbe A.

Pharmacol Res. 2016 Sep;111:859-866. doi: 10.1016/j.phrs.2016.07.036. Epub 2016 Jul 30.

PMID:
27480202
24.

The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.

Rusz O, Pál M, Szilágyi É, Rovó L, Varga Z, Tomisa B, Fábián G, Kovács L, Nagy O, Mózes P, Reisz Z, Tiszlavicz L, Deák P, Kahán Z.

Pathol Oncol Res. 2017 Apr;23(2):253-264. doi: 10.1007/s12253-016-0088-z. Epub 2016 Jul 13.

PMID:
27411922
25.

Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group.

Lakatos G, Balázs A, Kui B, Gódi S, Szücs Á, Szentesi A, Szentkereszty Z, Szmola R, Kelemen D, Papp R, Vincze Á, Czimmer J, Pár G, Bajor J, Szabó I, Izbéki F, Halász A, Leindler L, Farkas G Jr, Takács T, Czakó L, Szepes Z, Hegyi P, Kahán Z.

J Gastrointestin Liver Dis. 2016 Jun;25(2):219-25. doi: 10.15403/jgld.2014.1121.252.pcr.

26.

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.

Zielinski C, Lang I, Beslija S, Kahan Z, Inbar MJ, Stemmer SM, Anghel R, Vrbanec D, Messinger D, Brodowicz T.

Br J Cancer. 2016 Jan 19;114(2):163-70. doi: 10.1038/bjc.2015.419. Epub 2015 Dec 10.

27.

A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort.

Balázs A, Németh BC, Ördög B, Hegyi E, Hritz I, Czakó L, Czimmer J, Gódi S, Csiszkó A, Rakonczay Z Jr, Párniczky A, Izbéki F, Halász A, Kahán Z, Hegyi P, Sahin-Tóth M; Hungarian Pancreatic Study Group.

Pancreas. 2016 Apr;45(4):541-5. doi: 10.1097/MPA.0000000000000539.

28.

Cardiac Surveillance Findings During Adjuvant and Palliative Trastuzumab Therapy in Patients with Breast Cancer.

Valicsek E, Kószó R, Dobi Á, Uhercsák G, Varga Z, Vass A, Jebelovszky É, Kahán Z.

Anticancer Res. 2015 Sep;35(9):4967-73.

PMID:
26254396
29.

Partial breast radiotherapy with simple teletherapy techniques.

Fekete G, Újhidy D, Együd Z, Kiscsatári L, Marosi G, Kahán Z, Varga Z.

Med Dosim. 2015 Winter;40(4):290-5. doi: 10.1016/j.meddos.2015.03.006. Epub 2015 Apr 18.

PMID:
25899875
30.

One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.

Rusz O, Vörös A, Varga Z, Kelemen G, Uhercsák G, Nikolényi A, Ormándi K, Simonka Z, Kahán Z.

Pathol Oncol Res. 2015 Sep;21(4):977-84. doi: 10.1007/s12253-015-9911-1. Epub 2015 Mar 10.

PMID:
25753983
31.

Low dose cranial irradiation-induced cerebrovascular damage is reversible in mice.

Sándor N, Walter FR, Bocsik A, Sántha P, Schilling-Tóth B, Léner V, Varga Z, Kahán Z, Deli MA, Sáfrány G, Hegyesi H.

PLoS One. 2014 Nov 13;9(11):e112397. doi: 10.1371/journal.pone.0112397. eCollection 2014.

32.

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.

Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C.

Br J Cancer. 2014 Nov 25;111(11):2051-7. doi: 10.1038/bjc.2014.504. Epub 2014 Sep 30.

33.

[Therapeutic significance of sunitinib-induced "off-target" side effects].

Maráz A, Cserháti A, Uhercsák G, Szilágyi E, Varga Z, Kahán Z.

Magy Onkol. 2014 Sep;58(3):167-72. Epub 2014 Aug 2. Hungarian.

34.

Radiation dose to the nodal regions during prone versus supine breast irradiation.

Csenki M, Ujhidy D, Cserháti A, Kahán Z, Varga Z.

Ther Clin Risk Manag. 2014 May 21;10:367-72. doi: 10.2147/TCRM.S59483. eCollection 2014.

35.

[Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].

Maráz A, Bodoky G, Dank M, Géczi L, Kahán Z, Mangel L, Révész J, Szűcs M.

Magy Onkol. 2014 Mar;58(1):4-9. Epub 2014 Mar 4. Hungarian.

36.

Differential immunostaining of various types of breast carcinomas for growth hormone-releasing hormone receptor - Apocrine epithelium and carcinomas emerging as uniformly positive.

Kővári B, Rusz O, Schally AV, Kahán Z, Cserni G.

APMIS. 2014 Sep;122(9):824-31. doi: 10.1111/apm.12224. Epub 2014 Jan 31.

PMID:
24479854
37.

Delays in diagnosis and treatment of breast cancer: a multinational analysis.

Jassem J, Ozmen V, Bacanu F, Drobniene M, Eglitis J, Lakshmaiah KC, Kahan Z, Mardiak J, Pieńkowski T, Semiglazova T, Stamatovic L, Timcheva C, Vasovic S, Vrbanec D, Zaborek P.

Eur J Public Health. 2014 Oct;24(5):761-7. doi: 10.1093/eurpub/ckt131. Epub 2013 Sep 12.

PMID:
24029456
38.

Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.

Maráz A, Furák J, Varga Z, Fodor E, Együd Z, Borzási E, Kahán Z, Pálföldi R, Tiszlavicz L, Hideghéty K.

Anticancer Res. 2013 Apr;33(4):1737-41.

PMID:
23564825
39.

Thrombocytosis has a negative prognostic value in lung cancer.

Maráz A, Furák J, Varga Z, Kahán Z, Tiszlavicz L, Hideghéty K.

Anticancer Res. 2013 Apr;33(4):1725-9.

PMID:
23564823
40.

Individualized positioning for maximum heart protection during breast irradiation.

Varga Z, Cserháti A, Rárosi F, Boda K, Gulyás G, Együd Z, Kahán Z.

Acta Oncol. 2014 Jan;53(1):58-64. doi: 10.3109/0284186X.2013.781674. Epub 2013 Apr 2.

PMID:
23544358
41.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group.

Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

PMID:
23312888
42.

Bone homeostasis and breast cancer: implications for complex therapy and the maintenance of bone integrity.

Rusz O, Kahán Z.

Pathol Oncol Res. 2013 Jan;19(1):1-10. doi: 10.1007/s12253-012-9586-9. Epub 2012 Dec 5. Review.

PMID:
23212591
43.

Radioguided occult lesion localisation versus wire-guided lumpectomy in the treatment of non-palpable breast lesions.

Takács T, Paszt A, Simonka Z, Abrahám S, Borda B, Ottlakán A, Ormándi K, Lázár M, Vörös A, Kahán Z, Lazar G.

Pathol Oncol Res. 2013 Apr;19(2):267-73. doi: 10.1007/s12253-012-9578-9. Epub 2012 Oct 14.

PMID:
23065470
44.

The relationship of multifocality and tumor burden with various tumor characteristics and survival in early breast cancer.

Kelemen G, Farkas V, Debrah J, Ormandi K, Voros A, Kaizer L, Varga Z, Lazar G, Kahan Z.

Neoplasma. 2012;59(5):566-73. doi: 10.4149/neo_2012_073.

PMID:
22668023
45.

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

Lang I, Inbar MJ, Kahán Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C.

Eur J Cancer. 2012 Nov;48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26.

PMID:
22640829
46.

[Modern pharmacological therapy of breast cancer].

Láng I, Kahán Z, Hitre E, Dank M, Rubovszky G, Horváth Z, Kásler M.

Orv Hetil. 2012 Jan 15;153(2):56-65. doi: 10.1556/OH.2012.29257. Review. Hungarian.

PMID:
22217685
47.

Cosmetic outcome 1-5 years after breast conservative surgery, irradiation and systemic therapy.

Kelemen G, Varga Z, Lázár G, Thurzó L, Kahán Z.

Pathol Oncol Res. 2012 Apr;18(2):421-7. doi: 10.1007/s12253-011-9462-z. Epub 2011 Oct 8.

PMID:
21984131
48.

Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

Oncology. 2011;80(3-4):269-77. doi: 10.1159/000329038. Epub 2011 Jul 7.

PMID:
21734419
49.

Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.

Nikolényi A, Uhercsák G, Csenki M, Hamar S, Csörgo E, Tánczos E, Thurzó L, Brodowicz T, Wagnerova M, Kahán Z.

Pathol Oncol Res. 2012 Jan;18(1):61-8. doi: 10.1007/s12253-011-9417-4. Epub 2011 Jun 18.

PMID:
21681601
50.

Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients.

Varga Z, Cserháti A, Kelemen G, Boda K, Thurzó L, Kahán Z.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1109-16. doi: 10.1016/j.ijrobp.2010.03.044. Epub 2011 May 5.

PMID:
21549513

Supplemental Content

Support Center